Accueil   Diary - News   All news Ecrins Therapeutics lance une levée de fonds

Ecrins Therapeutics lance une levée de fonds

Created in 2010, Ecrins Therapeutics develops an innovative anticancer drug, ET-D5, which is a first-in-class protein phosphatase inhibitor with proven in vivo efficacy.

We plan to quickly develop ET-D5 for the treatment of agressive cancers, such as tumors of kidney, pancreas, liver or sarcomas. The 1st clinical trial has been already programmed for the begining 2016 at the Centre Léon Bérard (Lyon). We are raising 500 K€ in order to complete the last steps leading to clinicals trials, namely regulatory toxicology studies.